ストックスクリーナーアプリを入手
26.06
0.04%
0.010
プレマーケット:
26.02
-0.04
-0.15%
Arcus Biosciences Inc (RCUS) 最新ニュース
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88 - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q1 Revenue $17.0M, vs. FactSet Est of $29.5M - marketscreener.com
Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Arcus Biosciences (RCUS) Q1 2026 loss widens amid Gilead shift and trial setback - Stock Titan
Arcus Biosciences (NYSE: RCUS) details Q1 loss, cash runway and trial shifts - Stock Titan
Arcus lines up 2026 kidney cancer trial milestones with $876M cash - Stock Titan
MSN Money - MSN
Arcus Biosciences in the spotlight: Earnings test casdatifan focus By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Kno - GuruFocus
Understanding Momentum Shifts in (RCUS) - Stock Traders Daily
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study - TipRanks
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes - Sahm
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday - MarketBeat
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now - Seeking Alpha
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift - Yahoo Finance
New Arcus hire gets 4,200 options and 2,100 RSUs under plan - Stock Titan
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last? - MSN
RCUS insider files Form 144; plans to sell 53,826 shares (NYSE: RCUS) - Stock Titan
Arcus Biosciences stock hits 52-week high at 26.5 USD By Investing.com - Investing.com India
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year HighShould You Buy? - MarketBeat
Avoiding Lag: Real-Time Signals in (RCUS) Movement - Stock Traders Daily
What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
Arcus Biosciences (RCUS) Sees 12.2% Surge in Stock Price - GuruFocus
Arcus Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Arcus Biosciences (NYSE:RCUS) Trading Up 12.7%Here's Why - MarketBeat
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? - Yahoo Finance
[ARS] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences : to Host Conference Call to Discuss First-Quarter 2026 Financia... - marketscreener.com
Cancer drug developer Arcus sets May 5 webcast on Q1 results - Stock Titan
Arcus Biosciences (NYSE: RCUS) details 2026 virtual shareholder meeting votes - Stock Titan
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):